Ergomed’s expertise in rare disease clinical trials is showcased through our recent Phase III study on Anti-GBM (Goodpasture’s) Disease.
By implementing rapid site activation, expanding our European network, and ensuring high-level communication between investigators, we overcame recruitment challenges in this complex, low-prevalence condition. Our strategic approach is driving the trial towards success, with key milestones already achieved.